 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12345678910111213...1415» |
- RARE CASE OF WALLENBERG SYNDROME CAUSING AUDIBLE STRIDOR SUCCESSFULLY TREATED WITH HELIOX THERAPY (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3136;
- ||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment closed: ORIGINAL: A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity (clinicaltrials.gov) - Jul 27, 2023
P3, N=1490, Active, not recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Enrollment open: Intravenous Tenecteplase Plus EVT Versus EVT Alone on 4.5 to 24 Hours After Basilar Artery Occlusion (clinicaltrials.gov) - Jul 20, 2023
P3, N=332, Recruiting, Sponsor: The First Affiliated Hospital of University of Science and Technology of China
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Retrospective data, Journal, HEOR: Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke: The Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERTAIN) Collaboration. (Pubmed Central) - Jul 14, 2023
In this large study, ischemic stroke treatment with 0.25-mg/kg tenecteplase was associated with lower odds of sICH than treatment with alteplase. The results provide evidence supporting the safety of tenecteplase for stroke thrombolysis in real-world clinical practice.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Use of Tenecteplase in Acute Ischemic Stroke in the Time of SARS-CoV-2. (Pubmed Central) - Jul 13, 2023
The easier administration of TNK has improved the accessibility of fibrinolytic therapy, even in adverse circumstances, such as the COVID-19 pandemic. Its use appears to be safe and effective, even in patients who are not candidates for mechanical thrombectomy.
- |||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Clinical: Given its ease of administration, tenecteplase should be used as a first-line thrombolytic agent for LVO stroke. Thanks to my mentors and coauthors: @AlmekhlafiMa @bijoymenon @nishita_singh3 @DrRickSwartz @dr_sajobi @mihill68 @brianhb @VancouverStroke @SCouttsMD et al. (Twitter) - Jul 11, 2023
- || TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Journal: Safety and Efficacy of Tenecteplase Compared With Alteplase in Patients With Large Vessel Occlusion Stroke: A Prespecified Secondary Analysis of the ACT Randomized Clinical Trial. (Pubmed Central) - Jul 10, 2023
No difference was noted in successful reperfusion rates in the first (19 [9.2%] vs 21 [10.5%]) and final angiogram (174 [84.5%] vs 177 [88.9%]) among 405 patients who underwent thrombectomy. The findings in this study indicate that intravenous tenecteplase conferred similar reperfusion, safety, and functional outcomes compared to alteplase among patients with LVO.
- || TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: Evolving Thrombolytics: from Alteplase to Tenecteplase. (Pubmed Central) - Jun 19, 2023
This paper provides an overview of completed and ongoing randomized trials and nonrandomized studies analyzing tenecteplase in the treatment of acute ischemic stroke. Results reviewed support the safe use of tenecteplase in clinical practice.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Efficacy of intravenous thrombolysis with tenecteplase in treating the branch atheromatous disease (Pubmed Central) - Jun 16, 2023
The 90-day mortality in the control group was 2.2% (1/46), while no death was detected in the TNK group. Intravenous thrombolysis therapy with TNK can not only increase the proportion of 90-day mRS 0-2 in BAD patients, but also reduce the incidence of END.
- || TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Review, Journal: Tenecteplase: A Review of Its Pharmacology and Uses. (Pubmed Central) - Jun 12, 2023
Intravenous thrombolysis therapy with TNK can not only increase the proportion of 90-day mRS 0-2 in BAD patients, but also reduce the incidence of END. No abstract available
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Left Ventricular Global Longitudinal Strain Following Acute ST-Elevation Myocardial Infarction - A Comparison of Primary Coronary Angioplasty and Tenecteplase-Based Pharmacological Reperfusion Strategy. (Pubmed Central) - Jun 12, 2023
There were no significant differences in mortality and inhospital complications in both groups. Global LV systolic function is significantly better after primary coronary angioplasty as compared to TNK-based pharmacological reperfusion therapy when assessed by routine LVEF and 2D GLS in the setting of acute STEMI.
- || TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Review, Journal: Supporting Post-Stroke Language and Cognition with Pharmacotherapy: Tools for Each Phase of Care. (Pubmed Central) - Jun 12, 2023
Currently there are no drugs approved in the United States for the treatment of aphasia. Nevertheless, pharmacological intervention may provide a benefit to all phases of stroke care.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Intravenous thrombolysis of ischemic stroke-Current status (Pubmed Central) - Jun 12, 2023
The most recent guidelines indicate that TNK is particularly advantageous over rtPA in patients treated in combination with endovascular stroke therapy (EST). The combination of IVT and EST should primarily be performed in the 4.5?h time window in patients without contraindications; in the later time window EST alone is conceivable if it can be performed without delay.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Femoral Access-Site Complications with Tenecteplase versus Alteplase before Mechanical Thrombectomy for Large-Vessel-Occlusion Stroke. (Pubmed Central) - Jun 12, 2023
The combination of IVT and EST should primarily be performed in the 4.5?h time window in patients without contraindications; in the later time window EST alone is conceivable if it can be performed without delay. Tenecteplase compared with alteplase before mechanical thrombectomy for large-vessel-occlusion stroke is not associated with an alteration in femoral access-site complication rates.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment open: DIVAr (clinicaltrials.gov) - Jun 12, 2023
P=N/A, N=300, Recruiting, Sponsor: Centre Hospitalier Sud Francilien
Tenecteplase compared with alteplase before mechanical thrombectomy for large-vessel-occlusion stroke is not associated with an alteration in femoral access-site complication rates. Not yet recruiting --> Recruiting
- | Aggrastat (tirofiban) / Correvio, Medicure
Enrollment open: TITACIPPI: Tirofiban Plus Intravenous Thrombolysis in Acute Anterior Choroidal Infarction or Paramedian Pontine Infarction (clinicaltrials.gov) - Jun 12, 2023
P=N/A, N=60, Recruiting, Sponsor: Centre Hospitalier Sud Francilien
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Review, Journal: UpdatED: The emergency medicine pharmacotherapy literature of 2022. (Pubmed Central) - Jun 5, 2023
Pharmacotherapy-related publications deemed to be GRADE 1A and 1B were reviewed by the group for inclusion in the review. In all, this article summarizes and provides commentary on the potential clinical impact of 13 articles, 4 guidelines, and 3 meta-analyses covering topics including anticoagulant reversal, tenecteplase in acute ischemic stroke, guideline updates for heart failure and aortic aneurysm, magnesium in atrial fibrillation, sedation in mechanically ventilated patients and pain management strategies in the Emergency Department (ED), and tranexamic acid use in epistaxis and GI bleed.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal, Head-to-Head: Tenecteplase versus alteplase in treatment of acute ST-segment elevation myocardial infarction: a randomized non-inferiority trial. (Pubmed Central) - Jun 2, 2023
P4
In all, this article summarizes and provides commentary on the potential clinical impact of 13 articles, 4 guidelines, and 3 meta-analyses covering topics including anticoagulant reversal, tenecteplase in acute ischemic stroke, guideline updates for heart failure and aortic aneurysm, magnesium in atrial fibrillation, sedation in mechanically ventilated patients and pain management strategies in the Emergency Department (ED), and tranexamic acid use in epistaxis and GI bleed. rhTNK-tPA was non-inferior to rt-PA in the effect of improving recanalization of the infarct-related artery, a validated surrogate of clinical outcomes, among Chinese patients with acute STEMI.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Improving neurological outcome for acute basilar artery occlusion with sufficient recanalization after thrombectomy by intraarterial tenecteplase (INSIST-IT): Rationale and design. (Pubmed Central) - May 30, 2023
Subgroup analysis of the primary outcome will be performed by age, gender, baseline NIHSS score, baseline pc-ASPECTS, intravenous thrombolysis, time from estimated symptom onset to treatment, mTICI, blood glucose, and stroke etiology. The results of this study will provide evidence of whether adjunct use of intraarterial tenecteplase after successful reperfusion with EVT is associated with better outcomes for acute BAO patients.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness of tenecteplase versus alteplase for stroke thrombolysis evaluation trial in the ambulance. (Pubmed Central) - May 30, 2023
Treatment of ischaemic stroke patients with tenecteplase appeared to be cost-effective and improve QALYs in the MSU setting based on Phase II data. The reduced total cost from tenecteplase was driven by savings from acute hospitalisation and reduce need for nursing home care.
- |||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Trial completion date, Trial primary completion date: EXTEND-IV: Randomization to Extend Stroke Intravenous ThromboLysis In Evolving Non-Large Vessel Occlusion With TNK (RESILIENT (clinicaltrials.gov) - May 26, 2023
P3, N=642, Recruiting, Sponsor: Hospital Moinhos de Vento
The reduced total cost from tenecteplase was driven by savings from acute hospitalisation and reduce need for nursing home care. Trial completion date: May 2024 --> Jan 2027 | Trial primary completion date: Jan 2024 --> Jan 2026
- || TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Review, Journal: Tenecteplase in Acute Stroke: What About the Children? (Pubmed Central) - May 25, 2023
Changes in fibrinolytic capacity over childhood, pediatric pharmacological considerations such as age-specific differences in drug clearance and volume of distribution, and practical aspects of drug delivery such as availability in children's hospitals may impact decisions about transitioning from alteplase to tenecteplase for acute pediatric stroke treatment. Pediatric and adult neurologists should prepare institution-specific guidelines and organize prospective data collection.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Trial completion date, Trial primary completion date: Improving Neuroprotective Strategy for Ischemic Stroke With Poor Recanalization After Thrombectomy by Intra-arterial TNK (INSIST-TNK) (clinicaltrials.gov) - May 25, 2023
P=N/A, N=30, Recruiting, Sponsor: Hui-Sheng Chen
Pediatric and adult neurologists should prepare institution-specific guidelines and organize prospective data collection. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Follow-up Imaging After Thrombolysis: FIAT, A Randomized Trial. (Pubmed Central) - May 15, 2023
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 It is likely safe to forgo follow up imaging after thrombolysis in the absence of clinical decompensation.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion, Trial completion date: AcTQuICR: Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke (clinicaltrials.gov) - May 12, 2023
P3, N=1600, Completed, Sponsor: University of Calgary
It is likely safe to forgo follow up imaging after thrombolysis in the absence of clinical decompensation. Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Apr 2023
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Intra-arterial tenecteplase is safe and may improve the first-pass recanalization for acute ischemic stroke with large-artery atherosclerosis: the BRETIS-TNK trial. (Pubmed Central) - May 5, 2023
P=N/A
There was a trend toward higher proportion of functional independence at 90?days in the BRETIS-TNK comparing with the control group (50% vs. 32%, p?=?0.11). This is the first study to report that intra-arterial TNK during the first pass of EVT seems safe and feasible in AIS-LVO patients.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY (TenCRAOS) (A3) - Apr 21, 2023 - Abstract #EAN2023EAN_2335;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Real-life experience using tenecteplase versus alteplase in acute ischemic stroke outside conventional indications (A3) - Apr 21, 2023 - Abstract #EAN2023EAN_1585;
- || TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Enrollment open, Trial completion date, Trial primary completion date: ALLY: Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy Pilot Trial (clinicaltrials.gov) - Apr 21, 2023
P2, N=20, Recruiting, Sponsor: ProMedica Health System
This is the first study to report that intra-arterial TNK during the first pass of EVT seems safe and feasible in AIS-LVO patients. Not yet recruiting --> Recruiting | Trial completion date: Jun 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
INTRACRANIAL HEMORRHAGE PATTERNS AND ASSOCIATION WITH CLINICAL OUTCOME IN ACUTE STROKE TREATED WITH TENECTEPLASE VERSUS ALTEPLASE: RESULTS FROM THE ACT TRIAL (Paper Poster Area) - Apr 19, 2023 - Abstract #ESOC2023ESOC_1919;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
EARLY RECANALIZATION AMONG PATIENTS UNDERGOING BRIDGING THERAPY WITH TENECTEPLASE OR ALTEPLASE : A PROPENSITY MATCHED ANALYSIS (Paper Poster Area) - Apr 19, 2023 - Abstract #ESOC2023ESOC_1893;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
EFFICACY AND SAFETY OF INJECTION TENECTEPLASE IN 4.5 TO 24 HOURS IMAGING ELIGIBLE WINDOW PATIENTS WITH ACUTE ISCHEMIC STROKE (EAST-AIS) (Paper Poster Area) - Apr 19, 2023 - Abstract #ESOC2023ESOC_1453;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
TENECTEPLASE IN CENTRAL (Paper Poster Area) - Apr 19, 2023 - Abstract #ESOC2023ESOC_1452;
P3
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
INFLUENCE OF SEX ON PROGNOSIS AND DELAY OF CARE OF ACUTE ISCHEMIC STROKE TREATED BY TENECTEPLASE (Paper Poster Area) - Apr 19, 2023 - Abstract #ESOC2023ESOC_1341;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
ACT-COG: COGNITIVE OUTCOMES IN THE ALTEPLASE COMPARED TO TENECTEPLASE (ACT) TRIAL (Paper Poster Area) - Apr 19, 2023 - Abstract #ESOC2023ESOC_1315;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
ASSOCIATION OF WHITE MATTER DISEASE WITH OUTCOMES IN ACUTE STROKE PATIENTS RECEIVING ALTEPLASE AND TENECTEPLASE: RESULTS FROM THE ACT TRIAL (Paper Poster Area) - Apr 19, 2023 - Abstract #ESOC2023ESOC_1260;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
EFFECT MODIFICATION OF TREATMENT WITH TENECTEPLASE IN WAKE-UP STROKE BY PRESENCE OF MRI DWI/FLAIR MISMATCH OR CTP PENUMBRA: A SUBGROUP ANALYSIS OF THE TWIST TRIAL (Paper Poster Area) - Apr 19, 2023 - Abstract #ESOC2023ESOC_1258;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
SAFETY AND EFFICACY OF TENECTEPLASE VERSUS ALTEPLASE IN ACUTE STROKE PATIENTS WITH CAROTID TANDEM LESIONS: RESULTS FROM THE ACT TRIAL (Paper Poster Area) - Apr 19, 2023 - Abstract #ESOC2023ESOC_1187;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Glunomab: A Monoclonal Antibody Counteracting The Neurovascular And Neuroinflammatory Damages Induced Both By Endogenous Tpa And Fibrinolytic Agents (Alteplase Or Tenecteplase) After Ischemic Stroke (Room 14 - Plenary) - Apr 19, 2023 - Abstract #ESOC2023ESOC_954;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Cost-effectiveness of Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance trial (Room 14 - Plenary) - Apr 19, 2023 - Abstract #ESOC2023ESOC_953;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Bridging Therapy with Tenecteplase or Alteplase in patients with Low Diffusion-Weighed Imaging Alberta Stroke Program Early Computed Tomography Score (Room 14 - Plenary) - Apr 19, 2023 - Abstract #ESOC2023ESOC_950;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
A COST-UTILITY ANALYSIS OF TENECTEPLASE IN THE TREATMENT OF ACUTE ISCHAEMIC STROKE IN THE UNITED KINGDOM (Paper Poster Area) - Apr 19, 2023 - Abstract #ESOC2023ESOC_930;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
COST-EFFECTIVENESS OF TENECTEPLASE VERSUS ALTEPLASE FOR ACUTE ISCHEMIC STROKE (Paper Poster Area) - Apr 19, 2023 - Abstract #ESOC2023ESOC_929;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
TENECTEPLASE VERSUS ALTEPLASE IN A THROMBOEMBOLIC STROKE MODEL: DOES IT MATCH WITH CLINICAL TRIALS RESULTS? (Paper Poster Area) - Apr 19, 2023 - Abstract #ESOC2023ESOC_924;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
SAFETY OF TENECTEPLASE AS COMPARED TO ALTEPLASE IN OLDER PATIENTS (Paper Poster Area) - Apr 19, 2023 - Abstract #ESOC2023ESOC_582;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
INTRAVENOUS TENECTEPLASE COMPARED WITH ALTEPLASE FOR MINOR ISCHEMIC STROKE: A SUBGROUP ANALYSIS OF THE ACT RANDOMIZED CLINICAL TRIAL (Paper Poster Area) - Apr 19, 2023 - Abstract #ESOC2023ESOC_580;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
INFLUENCE OF AGE ON OUTCOMES IN PATIENTS RECEIVING ALTEPLASE AND TENECTEPLASE: (Paper Poster Area) - Apr 19, 2023 - Abstract #ESOC2023ESOC_579;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
INTRAVENOUS ALTEPLASE VERSUS TENECTEPLASE IN PATIENTS WITH ACUTE POSTERIOR CIRCULATION STROKES: SECONDARY ANALYSIS FROM THE ACT TRIAL (Paper Poster Area) - Apr 19, 2023 - Abstract #ESOC2023ESOC_576;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
SAFETY OF TENECTEPLASE VS ALTEPLASE IN STENT IMPLANTATION IN THE ACUTE ISCHEMIC STROKE (ePoster Area) - Apr 19, 2023 - Abstract #ESOC2023ESOC_558;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
EVALUATING THE USE OF INTRAVENOUS TENECTEPLASE FOR THE MANAGEMENT OF ACUTE ISCHEMIC STROKE IN THE MOBILE STROKE UNIT: AN INTERNATIONAL MULTI-INSTITUTIONAL SURVEY (ePoster Area) - Apr 19, 2023 - Abstract #ESOC2023ESOC_548;